Kenvue Inc. (NYSE:KVUE) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. While EPS exceeded expectations and there is optimism for the second half of the year, current financial metrics such as declining organic sales and margins pose concerns. The lack of a shareholder return plan and supply chain challenges also weigh negatively. However, the company's innovation and strategic initiatives, along with positive consumer responses, provide a balanced outlook. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.
Key Financial Performance
EPS $0.24, up from $0.2275 expectations.
Organic Sales Declined 1.2% year-over-year, attributed to a 3% to 4% headwind from destocking in China and strategic investments in price and trade spend in the U.S.
Adjusted Gross Margin 60%, down 20 basis points year-over-year, due to volume deleverage, unfavorable currency, inflationary headwinds, and price investments.
Adjusted Operating Margin 19.8%, down 220 basis points year-over-year, driven by increased support behind brands and significant investment initiated last year.
Adjusted Net Income $465 million, with a slight decrease in net interest expense to $94 million and adjusted effective tax rate down to 27.5%.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Launched new Beauty to a Science brand positioning for Neutrogena in February, supported by a 360-degree media campaign featuring Gen Z influencers.
Innovation in Skin Health: Rolling out Listerine Clinical Solutions outside the US and launching a new variant targeted at sensitivities in the US.
Expansion of Product Lines: Expanding Band-Aid brand and Aveeno Kids ranges with new products.
Market Share Growth: Tylenol gained share for the eleventh straight quarter, maintaining its number one position in the US.
Category Leadership: Zyrtec grew both value and volume share, strengthening Kenvue’s leadership in the allergy category.
Geographic Expansion: Aveeno brand saw double-digit growth in EMEA, with successful rollout in Central Europe.
Operational Efficiency: Completed Transition Services Agreement program, finalizing the exit of over 2,300 TSAs without disruption.
Cost Structure Optimization: Executing brand investments and pacing well towards realizing $350 million in gross annualized savings by 2026.
CFO Transition: Transitioning to new CFO Amit Banati on May 12, 2025, to support the next chapter of Kenvue.
Strategic Pricing Investments: Implementing strategic price investments and in-store activations in the US to enhance brand competitiveness.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs Impact: The company estimates a gross impact of nearly $150 million for 2025 due to tariffs implemented by the US and retaliatory measures by other countries. This will lead to higher costs for imported products and components.
Supply Chain Challenges: The company is facing supply chain challenges, particularly due to destocking in Asia, which is expected to affect performance in the near term.
Regulatory Issues: The evolving situation regarding tariffs remains fluid, which poses a risk to cost structures and pricing strategies.
Economic Factors: The company anticipates a dynamic macroeconomic environment in 2025, with potential impacts from seasonal incidents and retailer order management tightening.
Competitive Pressures: There are competitive pressures in certain geographies affecting organic sales, particularly in the Essential Health segment.
Market Deceleration: The company expects the categories and markets where it competes to decelerate towards the 2% to 3% range in 2025, driven by the absence of price increases.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Priorities: Kenvue is advancing three strategic priorities: 1) Activation of a new operating model to enhance innovation and marketing; 2) Optimization of cost structure through operational efficiencies; 3) Strengthening performance culture with new ways of working and a consolidated headquarters.
Operational Milestone: Completion of the Transition Services Agreement program, finalizing the exit of over 2,300 TSAs without disruption.
Innovation and Marketing: Kenvue is leveraging its 'five extraordinary powers' to enhance brand potential, including superior science and insights-led innovation.
New Headquarters: Kenvue has moved into a new global headquarters in Summit, New Jersey, consolidating seven US locations to improve collaboration.
Organic Sales Growth Outlook: Kenvue maintains its organic sales growth outlook for 2025 in the range of 2% to 4%.
Adjusted Operating Margin: Adjusted operating margin is expected to contract slightly for the full year due to increased costs from tariffs.
Adjusted Diluted EPS: Adjusted diluted EPS for 2025 is expected to be about flat versus last year, with low-single-digit growth on a constant currency basis.
Tariff Impact: Estimated gross impact of tariffs for 2025 is nearly $150 million, affecting costs and margins.
Currency Impact: Current FX rates are expected to have a 1% drag on top-line growth, improving from a previous estimate of 3%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Kenvue Inc. has not announced any specific share buyback program or dividend program during this earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide insights on the innovation plans for the year and how they have evolved given the current consumer pressures?
A:We have a strong plan for innovation and brand activation throughout 2025, with an expected acceleration in the back half of the year. We are tweaking our plans to ensure we offer the right value equation and are present where shoppers are. We are not planning to change our plans significantly, as innovation is crucial for our categories.
Q:Can you frame an expectation for second quarter organic growth versus the first quarter?
A:We do not guide by quarters, but we expect muted first half results followed by acceleration in the second half. Q2 organic sales growth will be burdened by destocking in Asia and strategic price investments in the US.
Q:What gives you confidence in the outlook for the back half of the year?
A:The back half will not have some of the headwinds affecting the first half. We have a strong commercial plan, more innovation, and are seeing positive consumer responses. We expect pricing to be a net positive.
Q:Can you elaborate on the building blocks of innovation in Skin Health and Beauty?
A:We are encouraged by positive signs in consumption and consumer reactions to our campaigns. We expect consumption to outpace organic sales growth in the first half of the year.
Q:How are you balancing promotional activity with marketing investment in Skin Health and Beauty?
A:We plan to invest more this year than last, focusing on responsible ROI. We are making progress in improving gross margins and expect margins to improve as consumption increases.
Q:Are you catching up to competitors in terms of price offerings?
A:We see consumers responding positively to our investments. We are not the cheapest but aim to hit the right psychological price points.
Q:What are your thoughts on supply chain risks and opportunities?
A:We are working to mitigate the impact of tariffs and have a resilient supply chain. We are also looking for opportunities created by the current situation.
Q:Can you explain the elevated SG&A as a percentage of sales?
A:We are investing more behind our brands and are on track to deliver $350 million in savings through our efficiency program.
Q:Are you seeing any trends in consumers trading down to private-label brands?
A:We do not see a down trade to private-label globally. Our brands continue to earn consumer confidence.
Q:What are your expectations regarding tariff impacts?
A:We have embedded a gross impact of $150 million for 2025 due to tariffs, with efforts in place to mitigate this impact.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific impacts of tariffs on pharmaceutical imports and the potential for future corporate actions similar to those seen at Kellogg's.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Allergy
Amit
Asia Pacific
Beauty sale
CAGNY
CFO transition
Care consumption
Health Beauty
Health sale
Skin Health
approach
brand category
category deceleration
category value
club channel
consumption sale
contribution price
destocking China
distribution
gap competition
household penetration
loss rotation
market share
medium campaign
milestone
offering
price investment
price trade
rotation club
share gap
share position
transition chapter
value volume
KVUE Transcript
Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call reveals several concerning factors: a downward revision of the 2025 outlook, declining sales across segments, supply chain issues, and high SG&A costs. Despite strategic priorities and some brand successes, management's vague responses in the Q&A and lack of concrete guidance further dampen sentiment. The negative financial trends, combined with external pressures like tariffs and competitive challenges, suggest a negative stock price reaction in the short term.
Kenvue Inc. (NYSE:KVUE) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents mixed signals. While EPS exceeded expectations and there is optimism for the second half of the year, current financial metrics such as declining organic sales and margins pose concerns. The lack of a shareholder return plan and supply chain challenges also weigh negatively. However, the company's innovation and strategic initiatives, along with positive consumer responses, provide a balanced outlook. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Unknown5-8
The earnings call reflects a challenging financial situation with declining organic sales, adjusted gross margin, and operating margin. The absence of a share buyback or dividend program further dampens investor sentiment. While management expressed optimism about innovation and growth in the latter half of the year, the lack of specific guidance and clarity in responses, particularly concerning tariff impacts and innovation success tracking, adds uncertainty. The overall sentiment is negative due to these factors, despite some positive consumer response and planned strategic investments.
Kenvue Inc. (NYSE:KVUE) Q4 2024 Earnings Call Transcript
Unknown2-7
The earnings call highlights several challenges: weak organic sales growth, distribution issues in Asia Pacific, and economic uncertainties. The lack of a share repurchase program and the operational separation risks add to investor concerns. Despite some positive elements like increased gross margin and brand investment, the overall sentiment is negative due to the financial outlook and management's vague responses during the Q&A. The absence of any strong positive catalysts, such as a new partnership or robust guidance, further supports a negative sentiment.
KVUE Slides
KVUE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
